Ann: 2015 AGM - Chairman's Address and CEO Presentation, page-5

If you dont do your fundamental analysis you'll always get caught out.

As I've indicated previously, margins continue to be squeezed. The only positive is that we are seeing increasing sales pcp.

The run up is all spec buying.

A very well respected soph investor (Farjoy) reduced holdings recently. While the proceeds were used for other investments they sold at an opportune time i.e overbought territory.

CLV isnt cheap. Its value should be somewhere between 27c-40c depending on your view re PH3 trials and the commercial impact of that. Better to sit and wait this one out. No hurry to reenter is the overarching pt.